171 related articles for article (PubMed ID: 36294800)
1. Nanomedicines Meet Disordered Proteins: A Shift from Traditional Materials and Concepts to Innovative Polymers.
Rizzuti B
J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294800
[TBL] [Abstract][Full Text] [Related]
2. HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery.
Chytil P; Kostka L; Etrych T
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33578756
[TBL] [Abstract][Full Text] [Related]
3. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
4. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
5. Structure-to-Efficacy Relationship of HPMA-Based Nanomedicines: The Tumor Spheroid Penetration Study.
Kudláčová J; Kotrchová L; Kostka L; Randárová E; Filipová M; Janoušková O; Fang J; Etrych T
Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33419291
[TBL] [Abstract][Full Text] [Related]
6. Polymer nanomedicines based on micelle-forming amphiphilic or water-soluble polymer-doxorubicin conjugates: Comparative study of in vitro and in vivo properties related to the polymer carrier structure, composition, and hydrodynamic properties.
Braunová A; Chytil P; Laga R; Šírová M; Machová D; Parnica J; Říhová B; Janoušková O; Etrych T
J Control Release; 2020 May; 321():718-733. PubMed ID: 32142741
[TBL] [Abstract][Full Text] [Related]
7. HPMA copolymers: origins, early developments, present, and future.
Kopecek J; Kopecková P
Adv Drug Deliv Rev; 2010 Feb; 62(2):122-49. PubMed ID: 19919846
[TBL] [Abstract][Full Text] [Related]
8. Design of smart HPMA copolymer-based nanomedicines.
Yang J; Kopeček J
J Control Release; 2016 Oct; 240():9-23. PubMed ID: 26437260
[TBL] [Abstract][Full Text] [Related]
9. Highly effective anti-tumor nanomedicines based on HPMA copolymer conjugates with pirarubicin prepared by controlled RAFT polymerization.
Randárová E; Nakamura H; Islam R; Studenovský M; Mamoru H; Fang J; Chytil P; Etrych T
Acta Biomater; 2020 Apr; 106():256-266. PubMed ID: 32058082
[TBL] [Abstract][Full Text] [Related]
10. Long-term biodistribution study of HPMA-ran-LMA copolymers in vivo by means of
Wagener K; Moderegger D; Allmeroth M; Reibel A; Kramer S; Biesalski B; Bausbacher N; Zentel R; Thews O; Rösch F
Nucl Med Biol; 2018 Mar; 58():59-66. PubMed ID: 29413458
[TBL] [Abstract][Full Text] [Related]
11. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.
Duncan R; Vicent MJ
Adv Drug Deliv Rev; 2010 Feb; 62(2):272-82. PubMed ID: 20005271
[TBL] [Abstract][Full Text] [Related]
12. HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations.
Lammers T; Subr V; Ulbrich K; Peschke P; Huber PE; Hennink WE; Storm G; Kiessling F
Nanomedicine (Lond); 2010 Dec; 5(10):1501-23. PubMed ID: 21143030
[TBL] [Abstract][Full Text] [Related]
13. Say no to drugs: Bioactive macromolecular therapeutics without conventional drugs.
Rütter M; Milošević N; David A
J Control Release; 2021 Feb; 330():1191-1207. PubMed ID: 33207257
[TBL] [Abstract][Full Text] [Related]
14. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
15. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.
Lammers T
Adv Drug Deliv Rev; 2010 Feb; 62(2):203-30. PubMed ID: 19951732
[TBL] [Abstract][Full Text] [Related]
16. Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors.
Buckway B; Wang Y; Ray A; Ghandehari H
Int J Pharm; 2013 Nov; 456(1):202-11. PubMed ID: 23933441
[TBL] [Abstract][Full Text] [Related]
17. POLYMERIC BIOMATERIALS AND NANOMEDICINES.
Yang J; Kopeček J
J Drug Deliv Sci Technol; 2015 Dec; 30(Pt B):318-330. PubMed ID: 26688694
[TBL] [Abstract][Full Text] [Related]
18. Synthetic macromolecular drug carriers: biodistribution of poly[(N-2-hydroxypropyl)methacrylamide] copolymers and their accumulation in solid rat tumors.
Kissel M; Peschke P; Subr V; Ulbrich K; Schuhmacher J; Debus J; Friedrich E
PDA J Pharm Sci Technol; 2001; 55(3):191-201. PubMed ID: 11417110
[TBL] [Abstract][Full Text] [Related]
19. Macromolecular nanotheranostics for multimodal anticancer therapy.
Huis In 't Veld R; Storm G; Hennink WE; Kiessling F; Lammers T
Nanoscale; 2011 Oct; 3(10):4022-34. PubMed ID: 21901211
[TBL] [Abstract][Full Text] [Related]
20. Polymer nitric oxide donors potentiate the treatment of experimental solid tumours by increasing drug accumulation in the tumour tissue.
Studenovsky M; Sivak L; Sedlacek O; Konefal R; Horkova V; Etrych T; Kovar M; Rihova B; Sirova M
J Control Release; 2018 Jan; 269():214-224. PubMed ID: 29154977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
